Search hospitals > South Carolina > Charleston
Ralph H. Johnson VA Medical Center, Charleston, SC
Claim this profileCharleston, South Carolina 29401
Global Leader in Post-Traumatic Stress Disorder
Global Leader in Stroke
Conducts research for Depression
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
163 reported clinical trials
22 medical researchers
Summary
Ralph H. Johnson VA Medical Center, Charleston, SC is a medical facility located in Charleston, South Carolina. This center is recognized for care of Post-Traumatic Stress Disorder, Stroke, Depression, Prostate Cancer, Lung Cancer and other specialties. Ralph H. Johnson VA Medical Center, Charleston, SC is involved with conducting 163 clinical trials across 212 conditions. There are 22 research doctors associated with this hospital, such as Oleksandra Lupak, Stephen J. Savage, Hongjun N Wang, PhD, and Jacobo Mintzer, MD.Top PIs
Oleksandra LupakRalph H Johnson VA Medical Center3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
24 drugs studied
Stephen J. SavageRalph H Johnson VA Medical Center2 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
7 reported clinical trials
10 drugs studied
Hongjun N Wang, PhDRalph H. Johnson VA Medical Center, Charleston, SC5 years of reported clinical research
Studies Chronic Pancreatitis
Studies Chronic Pain
4 reported clinical trials
6 drugs studied
Jacobo Mintzer, MDSouth Carolina Institute for Brain Health1 year of reported clinical research
Studies Alzheimer's Disease
Studies Dementia
4 reported clinical trials
6 drugs studied
Clinical Trials running at Ralph H. Johnson VA Medical Center, Charleston, SC
Prostate Cancer
Lung Cancer
Bladder Cancer
Stroke
Esophageal cancer
Post-Traumatic Stress Disorder
Depression
Non-Small Cell Lung Cancer
Multiple Myeloma
Pancreatic Cancer
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Capivasertib + Abiraterone
for Prostate Cancer
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.
Recruiting1 award Phase 2
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting1 award N/A5 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ralph H. Johnson VA Medical Center, Charleston, SC?
Ralph H. Johnson VA Medical Center, Charleston, SC is a medical facility located in Charleston, South Carolina. This center is recognized for care of Post-Traumatic Stress Disorder, Stroke, Depression, Prostate Cancer, Lung Cancer and other specialties. Ralph H. Johnson VA Medical Center, Charleston, SC is involved with conducting 163 clinical trials across 212 conditions. There are 22 research doctors associated with this hospital, such as Oleksandra Lupak, Stephen J. Savage, Hongjun N Wang, PhD, and Jacobo Mintzer, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.